UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 17, 2015
Trovagene, Inc.
(Exact name of registrant as specified in its charter)
Delaware |
| 001-35558 |
| 27-2004382 |
(State or other jurisdiction |
| (Commission File |
| IRS Employer |
of incorporation or organization) |
| Number) |
| Identification No.) |
11055 Flintkote Avenue, Suite A
San Diego, CA 92121
(Address of principal executive offices)
Registrant’s telephone number, including area code: (858) 952-7570
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On April 17, 2015, Trovagene, Inc. (the “Company”) issued a press release announcing that clinical data presented at the 2015 European Lung Cancer Conference (ELCC) demonstrate that its urine-based Precision Cancer MonitoringSM (PCM) platform outperformed tissue biopsy for the detection and monitoring of EGFR T790M mutations in metastatic lung cancer patients. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
99.1 |
| Press Release of Trovagene, Inc. dated April 17, 2015 |